CervoMed Announces Publications in Major Peer-Reviewed Journals That Inform on Potential of Neflamapimod as a Disease-Modifying Therapy for the Major Dementias
Retrieved on:
Tuesday, October 24, 2023
Alzheimer's disease, CRVO, Attention, Plasma, AD, Three-body problem, Neurology, MD, Publication, CNS, DLB, HIV disease progression rates, Basal forebrain, Ganz railcar (Ferrocarriles Vascongados, short version), Dementia, Nature Communications, American Academy, Drug development, Brain, Lewy body, Patient, Molecular Neurodegeneration, Pharmaceutical industry, Medical imaging
BOSTON, Oct. 24, 2023 /PRNewswire/ -- CervoMed Inc. (NASDAQ: CRVO), a clinical stage company focused on developing treatments for degenerative diseases of the brain, today announced the publication of the following two articles that support advancing neflamapimod as a disease-modifying treatment for Dementia with Lewy Bodies (DLB) and Alzheimer's Disease (AD):
Key Points:
- Neurology® is the medical journal of the American Academy of Neurology.
- The journal has released the final publication, including a Short Version in print, of the article that was the subject of a press release from CervoMed dated September 6th, 2023.
- Alam J and Nixon RA, Drug development targeting degeneration of the basal forebrain cholinergic system: its time has come.
- "As reported in Nature Communications last year, the primary analysis of the phase 2a study of DLB showed neflamapimod significantly improved dementia severity and motor function.